Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. After winning a broader FDA label in metastatic castration-resistant prostate cancer (mCRPC) ...

With China's growing dominance in the biopharma sector as a hotspot for drug asse | A group of over 20 global pharma leaders ...

The top pharmacy benefit manager (PBM) in the U.S., CVS Caremark, will restore coverage to obesity products from Eli Lilly, ...

As AbbVie continues to capitalize on its ImmunoGen deal, the growth of commercial antibody-drug conjugate (ADC) Elahere, another of the acquired company’s clinical assets has crossed the FDA finish ...

In the U.S., many top brand-name drugs continue to get more expensive with age, while the same medicines often get cheaper in peer countries, according to an AARP Public Policy Institute ...

Placement on the plenary session of the upcoming ASCO 2026 annual meeting has significantly elevated enthusiasm around Akeso’s first-line non-small cell lung cancer data for its Summit ...

AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday ...

Outlook Therapeutics has notched a win in its uphill battle to commercialize an ophthalmic version of Roche’s Avastin ...

The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three years after a phase 3 flop led Takeda to withdraw its Exkivity from the EGFR exon 20 ...

A multi-billion-dollar acquisition within the radiopharmaceutical space could be percolating as Lantheus Holding considers a ...

Italy’s antitrust agency, the Italian Competition Authority (AGCM), is investigating Biogen and its Italian subsidiary over ...

Amid a nearly $1 billion GLP-1 manufacturing expansion that began in 2024, CMDO CordenPharma is doubling down on its peptide capacity ambitions. The company—which already boasts production operations ...